Introduction
============

Tuberculosis (TB) is still one of the most lethal infectious diseases worldwide \[[@B1]\]. The only TB vaccine available for human use is the bacille Calmette-Guerin (BCG), an attenuated strain of *Mycobacterium bovis*\[[@B2]\]. However, this vaccine protects only against the most severe forms of the disease during childhood and their effectiveness has failed in the adult population. In recent years various glycolipids of the mycobacterial cell wall have become attractive candidates for a vaccine against TB because they constitute important virulence factors for initiating the establishment of infection by MTB \[[@B3]\]. These glycolipids have been demonstrated to be capable of stimulating T lymphocytes through the presentation by CD1 molecules \[[@B4]\]. In addition, mycobacterium lipids have been shown to induce protection in certain experimental animal models against infection by MTB \[[@B5],[@B6]\]. Some of these glycolipids are present in the cell wall of Mycobacterium smegmatis (Ms), a non-pathogenic mycobacteria of rapid growth, which has been used as a study model for TB. Liposomes prepared from glycolipids of Ms have also been reported to possess immunoadjuvant capacity \[[@B7]\]. Hence, it is interesting to evaluate the use of cell wall glycolipids of Ms as potential vaccine candidates against TB. Therefore, this study aims to assess the humoral immune response and cross reactivity induced by immunization of mice with liposomes containing a mixture of Ms total lipids and commercial lipids against MTB cell wall antigens.

Materials and methods
=====================

Total lipids from Ms mc^2^ 155 were extracted according to the methodology proposed by Rosenkrands et al \[[@B8]\]. Briefly, 30 mL of chloroform: methanol (2:1) was added to 10 g wet weight of biomass and mixed in a shaker overnight at room temperature. The chloroform phase and the extracted lipids were analyzed by one dimensional TLC. Liposomes were prepared according to the technical procedure of dehydration-rehydration \[[@B9]\]. Lipid composition of liposomes was basically distearoyl phosphatidyl choline (Sigma) and cholesterol (Sigma) at a molar ratio 1:1. Ten mg of Ms total lipids was then added to this mixture. Balb/c mice between 8 to 12 weeks were used in this study. Mice were divided into 4 groups of 10 animals each and were immunized subcutaneously with the appropriate preparation obtained as described below. Two control groups were used: the negative control group received 0.1 mL of PBS and the positive control group recieved 5 x 10^6^ CFU of *M. bovis* BCG Danish strain. Another group received 0.1 mL of a liposomal preparation formulated with commercial lipids (LipE) and a third group was inoculated with 0.1 mL of a liposomal preparation containing 1 mg of Ms total lipids and commercial lipids (LipMs). Groups inoculated with the liposome preparation (LipE and LipMs) received 3 doses administered 21 days apart from each other. The humoral immune response and cross reactivity against MTB was evaluated by indirect ELISA using Ms total lipid and subcellular fraction of MTB cell wall (CW), respectively.

Results and discussion
======================

Recognition of Ms total lipids by IgG antibodies in the sera of animals immunized with LipMs (Figure [1](#F1){ref-type="fig"}), was significantly higher than that of other groups. However, no significant differences were observed in the sera of animals inoculated with LipE and PBS against lipids from Ms. This result shows that the response obtained with LipMs, is due to the presence of the lipids from Ms and not to the commercial lipids used for preparation of liposomes. IgG antibodies against CW of MTB and BCG was detected in the sera of animals immunized with LipMs (Figure [2](#F2){ref-type="fig"}). The cross reactivity is possibly due to the presence of some glycolipids in the LipMs that share epitopes in common with MTB and BCG. Moreover, TLC analysis showed the presence of several common polar glycolipids in Ms and MTB like phosphatidylinositol mannosides (PIMs). This lipids have been demonstrated to play an important role in the infection of macrophages and to have the potential to induce humoral immune response capable of conferring protection against infection with MTB in experimental mouse models \[[@B10]\].
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In this study, we demonstrated that total lipids of Ms included in liposomes are able to induce humoral immune response in mice and posses cross-reactivity to MTB. These results support the strategy of employing Ms as a possible source of lipid antigens to be part of a vaccine candidate against TB.
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